Developing Viability Index for Machine Perfused Livers
Launched by MASSACHUSETTS GENERAL HOSPITAL · Oct 1, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new technology called machine perfusion, which helps preserve and improve discarded livers so they can potentially be used for transplantation. The goal is to develop a “viability index,” a set of guidelines to determine how suitable a machine-perfused liver is for transplanting. Researchers will collect samples from these livers before and after they are implanted in patients to analyze their function and identify important indicators that suggest whether a liver will work well after the transplant.
To participate in this trial, you need to be between 18 and 75 years old and a candidate for receiving a liver from a deceased donor. Unfortunately, if you are HIV positive, you would not be eligible. If you join the study, you can expect to provide liver samples and possibly receive a transplanted liver that has been improved through this innovative technique. Your participation could help advance the understanding of liver transplants and potentially improve outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female 18-75 years of age.
- • Candidate for a deceased-donor liver allograft.
- Exclusion Criteria:
- • Seropositivity for HIV-1.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Heidi Yeh, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials